Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Noah Holdings Q4 2025 Earnings Call - Profitability improved as AI-driven efficiency and investment-led revenue reshape the model
Noah reports a year of stabilization in revenue and a clear improvement in profit quality as it shifts from product sales toward investment-led, AI-enabled wealth management. Full year 2025 net revenu...
- Full year 2025 net revenue RMB 2.6 billion, broadly flat year-over-year; the company emphasizes quality of earnings over absolute top-line growth.
- Operating profit rose 22.5% to RMB 777 million; operating margin expanded to 29.8% from 24.4% a year earlier, driven by cost optimization and higher-margin investment income.
- Non-GAAP net income was RMB 612 million, up 11.2%; excluding two non-operational items (equity in affiliates loss and legacy credit fund provisions) adjusted non-GAAP net income would be about RMB 753 million.
- +12 more takeaways
Draganfly Q4 2025 Earnings Call - $50M Raise and Outrider Border Solution Fueling Global Demand
Draganfly closed 2025 with record revenue of CAD 7.7 million, but still reported a CAD 22.9 million comprehensive loss after non-cash items. Management emphasized a strategic shift from pure device sa...
- 2025 revenue rose 17.8% year-over-year to CAD 7.7 million, a company record.
- Full-year gross profit was CAD 1.32 million, down on an adjusted basis due to sales mix; adjusted gross margin fell to 20.4% from 30.9% in 2024.
- Total comprehensive loss for 2025 was CAD 22.9 million, including non-cash items; excluding those, adjusted comprehensive loss was roughly CAD 20.1 million.
- +9 more takeaways
Intrusion Inc. Q4 2025 Earnings Call - Government contract timing cost a quarter, revenue expected to land in H1 2026
Intrusion Inc. reported a year of product progress and partnerships, but a timing hit to a critical Department of War contract left Q4 revenue materially softer. Full year 2025 revenue rose 23% to $7....
- Q4 2025 revenue $1.5 million, down 25% sequentially and down 12% year-over-year, primarily due to delayed incremental funding on a major U.S. Department of War contract.
- Full year 2025 revenue $7.1 million, up 23% year-over-year, driven largely by expansion of the Department of War engagement.
- Management says expenses for the critical infrastructure deployment have already been recognized, but corresponding revenue was delayed, which will boost future quarters when funded.
- +13 more takeaways
KB Home Q1 2026 Earnings Call - Returning to Built-to-Order to Boost Backlog, Predictability, and H2 Margins
KB Home reported a quarter that met guidance but felt like a strategic pivot. Revenue and deliveries declined year over year, yet management has intentionally pulled back speculative starts and pushed...
- KB Home narrowed Q1 results to guidance: total revenues of $1.08 billion and diluted EPS of $0.52 for the quarter ended February 28, 2026.
- Deliveries were 2,370 homes in Q1, near the midpoint of guidance, down 23% year over year in housing revenues.
- Net orders rose 3% year over year to 2,846, but management said Q1 orders were below the level needed to sustain the prior full-year delivery plan, prompting a lower full-year guide.
- +13 more takeaways
Velo3D Q4 2025 Earnings Call - Defense Contracts and RPS Drive Record Backlog and Path to H2 2026 Profitability
Velo3D closed 2025 with clear momentum, anchored by defense qualifications, a growing Rapid Production Solutions business, and the company’s largest quarterly bookings ever that pushed backlog to abou...
- Record Q4 bookings lifted backlog to approximately $31 million, up from $16 million at year-end 2024 and $21 million at the prior quarter end, and management says the backlog is expected to convert within 12 months.
- Q4 revenue was $9.4 million, down 25% year over year from $12.6 million, while full year 2025 revenue was $46 million, up 12% from $41 million; excluding a $5 million 2024 licensing item, 2025 revenue grew 28% year over year.
- Gross margins were deeply negative in Q4 at negative 73.6%, driven largely by a non-recurring $7 million inventory obsolescence write-off; full year gross margin was negative 16.1% versus negative 5.1% in 2024.
- +12 more takeaways
Paysign Q4 2025 Earnings Call - Patient affordability scales, driving a clear margin inflection
Paysign closed 2025 with a classic growth-with-leverage story. Revenue rose 40.5% to $82.0 million, driven by a 168% surge in patient affordability revenue to $33.9 million and a steady plasma busines...
- 2025 results show scale and leverage: revenue +40.5% to $82.0 million, net income +98% to $7.6 million, adjusted EBITDA +107% to $19.9 million.
- Operating margin inflection: operating margin rose 723 basis points to 9.0% in 2025, reflecting improved gross margin (59.4% vs 55.1%) and disciplined OpEx growth.
- Patient affordability is the growth engine: pharma revenue grew 167.8% to $33.9 million, driven by 55 net program additions to 131 active programs and ~79% growth in claims processed.
- +12 more takeaways
Blaize Holdings, Inc. Q4 2025 Earnings Call - Rapid Q4 Revenue Ramp and Services Pivot Amid Large Noncash Losses
Blaize ended 2025 with a sharp revenue acceleration, from roughly $1 million in Q1 to $23.8 million in Q4, producing $38.6 million for the full year and beating guidance. Management is positioning the...
- Revenue ramped sharply in 2025, from about $1 million in Q1 to $23.8 million in Q4, producing $38.6 million for the full year and exceeding guidance.
- Company issued 2026 revenue guidance of $130 million, unchanged from prior guidance, with the first half expected to be lighter than the second.
- Blaize plans to launch the Blaize AI Services platform in Q2 2026 to unify hardware, software, and API-based services and shift monetization toward inference transactions and services.
- +12 more takeaways
Spectral AI Q4 2025 Earnings Call - BARDA $31.7M Boost as FDA De Novo Decision Looms, Commercial rollout pushed into 2026
Spectral AI closed 2025 with a substantive BARDA funding boost and a thicker cash cushion, while the company waits on a pivotal FDA De Novo decision that will determine whether DeepView moves from tri...
- Company submitted De Novo application to the FDA in June 2025, received an additional information request, and states it has timely replied, with management hopeful for a positive FDA response before the end of Q2 2026.
- Completed a 15-month burn validation study in March 2025 covering 164 adult and pediatric patients across 15 U.S. burn centers and EDs; Spectral says DeepView significantly outperformed clinical judgment and those results were included in the De Novo submission.
- BARDA remains a long-term partner; Project BioShield contract is worth up to $150 million, with $55 million previously awarded and an additional $31.7 million of advanced funding just granted.
- +12 more takeaways
Comstock Inc Full Year 2025 Earnings Call - Nevada Recycling Plant Nears Commissioning as Big Asset Monetizations Get Real
Comstock says 2025 was a transformation year. With an oversubscribed equity raise, a cleaned-up balance sheet and first-of-kind Nevada permits in hand, the company is moving from pilot to industrial s...
- Comstock closed an oversubscribed equity offering in January 2026, raising $57.5 million gross and about $53 million net, broadening its institutional shareholder base including Hood River, Gratia and MAK Capital.
- Liquidity snapshot: cash and cash equivalents were approximately $56 million at March 20, 2026, and common shares outstanding are about 74 million.
- 2025 metals revenue was modest: Comstock Metals reported roughly $1.4 million revenue in 2025 versus $4.4 million in 2024, plus about $2.2 million of additional billings treated as deferred revenue, which together approximate the $3.5 million guidance.
- +13 more takeaways
Absci Corporation Q4 2025 Earnings Call - ABS-201 in clinic with favorable safety, 13-week AGA proof-of-concept due H2 2026
Absci used the quarter to pivot from platform proof to a clinical push. ABS-201, a prolactin receptor blocking antibody engineered for extended half-life, has entered the clinic and the company has do...
- ABS-201 is in the clinic, with the company having dosed the first three SAD cohorts in the phase I/IIa HEADLINE trial and planning to dose SAD Cohort 4 and the first MAD cohort next.
- Emerging safety data are described as favorable, with no mechanism-related or off-target safety signals observed so far, though management cautioned the dataset is still small.
- Preliminary safety, tolerability, and PK readouts for HEADLINE are expected in the first half of 2026, a 13-week interim proof-of-concept (PoC) for AGA is planned for H2 2026, and full 26-week PoC data are expected in early 2027.
- +15 more takeaways